Aperio Further Strengthens Its Board of Directors with the Addition of Thomas Bologna

| May 23, 2011

More changes at Aperio.  As the below PR mentions, Mr. Bologna's appointment follows another board appointment last week (Mr. Scholotterbeck).  Aperio seems to be focusing increasingly on their clinical customers building on having a CMO, GM of Healthcare and a larger board presence with clinical market expertise.

VISTA, Calif.–(BUSINESS WIRE)– Aperio, the global leader in providing digital pathology solutions that improve patient care, today announced that it has appointed Thomas Bologna, President & Chief Executive Officer of Orchid Cellmark, Inc. (NASDAQ:ORCH - News), a leading service provider of DNA identity testing, to its Board of Directors. Last week, Aperio announced that healthcare veteran David Schlotterbeck had also joined its Board.

“Tom has created a tremendous legacy building and leading highly profitable, publicly held and venture-backed healthcare companies, and we are very fortunate to have him join our Board,” said Dirk G. Soenksen, Chairman and CEO of Aperio. “Tom’s strong operational experience in scaling companies and his deep domain knowledge in the diagnostics market in particular will strengthen Aperio’s ability to seize new opportunities in the dynamic digital pathology market.”

“Digital pathology is rapidly gaining momentum as a proven technology that is helping to reduce laboratory expenses, improve operational efficiencies, and significantly enhance patient care,” noted Bologna. “Aperio is in an excellent position to strengthen its lead in this growing market and I’m thrilled to be joining the company at this time.”

Prior to joining Orchid Cellmark, Bologna was Chief Executive Officer of Quorex Pharmaceuticals, a venture-backed company acquired by Pfizer Inc., and Ostex International, Inc. (NASDAQ:OSTX - News). Previously, he was Chief Executive Officer of Gen-Probe, a global leader in the development, manufacture and marketing of molecular diagnostics products and services, where he scaled the Company, took it public on NASDAQ and subsequently sold to Chugai Pharmaceutical Co. Bologna’s prior experience also includes senior-level positions with Becton Dickinson Diagnostic Systems, where he led the commercialization effort for the Company’s automated microbiology line.

This appointment represents a continued enhancement of Aperio’s leadership team. Recent additions include Keith Hagen as COO, Jared Schwartz, MD, PhD, as CMO, Patrick Yount as CFO, and Steven Russell as General Manager of Healthcare.

 


Category: Digital Pathology News, Pathology News

Comments are closed.